PMID- 34722263 OWN - NLM STAT- PubMed-not-MEDLINE VI - 11 TI - Single-Cell RNA Sequencing in Multiple Pathologic Types of Renal Cell Carcinoma Revealed Novel Potential Tumor-Specific Markers. PG - 719564 CI - Copyright © 2021 Su, Lv, Lu, Yu, Ye, Guo, Liu, Yan, Li, Zhang, Cheng and Mo. LA - eng PT - Journal Article PL - Switzerland TA - Front Oncol JT - Frontiers in oncology JID - 101568867 IS - 2234-943X (Print) LID - 10.3389/fonc.2021.719564 [doi] FAU - Su, Cheng AU - Su C AD - Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. AD - Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. AD - Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China. FAU - Lv, Yufang AU - Lv Y AD - Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. AD - Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. AD - Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China. FAU - Lu, Wenhao AU - Lu W AD - Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. AD - Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. AD - Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China. FAU - Yu, Zhenyuan AU - Yu Z AD - Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. AD - Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. AD - Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China. FAU - Ye, Yu AU - Ye Y AD - Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. AD - Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. AD - Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China. AD - Scientific Research Department, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China. FAU - Guo, Bingqian AU - Guo B AD - Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China. FAU - Liu, Deyun AU - Liu D AD - Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. AD - Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. FAU - Yan, Haibiao AU - Yan H AD - Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. AD - Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. FAU - Li, Tianyu AU - Li T AD - Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. AD - Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. FAU - Zhang, Qingyun AU - Zhang Q AD - Department of Urology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China. FAU - Cheng, Jiwen AU - Cheng J AD - Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. AD - Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. AD - Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China. FAU - Mo, Zengnan AU - Mo Z AD - Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. AD - Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. AD - Center for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China. IS - 2234-943X (Linking) OTO - NOTNLM OT - ScRNA-seq OT - cancer-associated fibroblasts OT - endothelial cells OT - renal cell carcinoma OT - single-cell RNA sequencing OT - tumor-immune microenvironment OT - tumor-specific markers PMC - PMC8551404 LR - 20211102 DP - 2021 DEP - 20211014 AB - Background: Renal cell carcinoma (RCC) is the most common type of kidney cancer. Studying the pathogenesis of RCC is particularly important, because it could provide a direct guide for clinical treatment. Given that tumor heterogeneity is probably reflected at the mRNA level, the study of mRNA in RCC may reveal some potential tumor-specific markers, especially single-cell RNA sequencing (scRNA-seq). Methods: We performed an exploratory study on three pathological types of RCC with a small sample size. This study presented clear-cell RCC (ccRCC), type 2 pRCC, and chRCC in a total of 30,263 high-quality single-cell transcriptome information from three pathological types of RCC. In addition, scRNA-seq was performed on normal kidneys. Tumor characteristics were well identified by the comparison between different pathological types of RCC and normal kidneys at the scRNA level. Results: Some new tumor-specific markers for different pathologic types of RCC, such as SPOCK1, PTGIS, REG1A, CP and SPAG4 were identified and validated. We also discovered that NDUFA4L2 both highly expressed in tumor cells of ccRCC and type 2 pRCC. The presence of two different types of endothelial cells in ccRCC and type 2 pRCC was also identified and verified. An endothelial cell in ccRCC may be associated with fibroblasts and significantly expressed fibroblast markers, such as POSTN and COL3A1. At last, by applying scRNA-seq results, the activation of drug target pathways and sensitivity to drug responses was predicted in different pathological types of RCC. Conclusions: Taken together, these findings considerably enriched the single-cell transcriptomic information for RCC, thereby providing new insights into the diagnosis and treatment of RCC.